Epidarex Capital, a leading transatlantic venture fund, today announced the launch of its therapeutic discovery engine, Epidarex Exeed Ltd. (Exeed). Focussed on advancing early stage, innovative life science assets, Exeed will pair world-class science with leading drug discovery, project management and CRO partners under the leadership of a highly experienced and skilled management team, with seed funds provided by Epidarex Capital.
Exeed has been founded to efficiently and rapidly transform breakthrough life science innovations into investable assets over a period of 12-18 months. The Exeed team, led by CEO Dr. Henning Steinhagen, with Daniel Gill and Richard Brooks in Operational and Finance roles, will provide significant hands-on support to de-risk early stage programs.
Dr Henning Steinhagen, CEO of Epidarex Exeed, said: “There is a clear need for early stage capital and capabilities that can validate and progress breakthrough life science innovation to a point where traditional VC investors are ready to fund companies and lead Series A investments. Epidarex Exeed will help to fulfil that need.”
Dr Liz Roper, Partner at Epidarex Capital added: “The formation of Epidarex Exeed and our investment in the company builds on our strong track record of backing innovative spin-outs from leading research universities across the UK and the US. We are excited that Dr. Steinhagen will lead the company, based on his wealth of experience in drug discovery and development.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005302/en/
Contacts:
Katie Odgaard
Zyme Communications
Tel: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com
